HighTower Advisors LLC Reduces Holdings in Certara, Inc. $CERT

Key Points

• HighTower Advisors LLC significantly reduced its holdings in Certara, Inc. by 87.0%, leaving the firm with 19,027 shares after selling 127,512 shares in the first quarter.
• Certara's stock has a current price of $10.58, with a market capitalization of $1.70 billion and a P/E ratio of 211.64, demonstrating substantial volatility in its price performance.
• Research analysts have mixed outlooks for Certara, with price targets ranging from $14.00 to $15.00, while the stock has received an average rating of "Moderate Buy."

HighTower Advisors LLC trimmed its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 87.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,027 shares of the company's stock after selling 127,512 shares during the period. HighTower Advisors LLC's holdings in Certara were worth $188,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of CERT. Versant Capital Management Inc boosted its holdings in shares of Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after buying an additional 1,866 shares in the last quarter. Wells Fargo & Company MN lifted its position in Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after acquiring an additional 1,047 shares during the period. Associated Banc Corp purchased a new position in Certara during the 1st quarter valued at about $101,000. Portside Wealth Group LLC purchased a new position in Certara during the 1st quarter valued at about $104,000. Finally, Janney Montgomery Scott LLC purchased a new position in Certara during the 1st quarter valued at about $120,000. Institutional investors own 73.96% of the company's stock.

Certara Price Performance

CERT opened at $10.58 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.16 and a current ratio of 2.16. The company's 50-day simple moving average is $10.81 and its two-hundred day simple moving average is $11.39. Certara, Inc. has a 52-week low of $8.64 and a 52-week high of $15.69. The stock has a market capitalization of $1.70 billion, a P/E ratio of 211.64 and a beta of 1.43.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a net margin of 1.97% and a return on equity of 5.11%. The company had revenue of $104.57 million for the quarter, compared to analysts' expectations of $104.14 million. During the same period in the previous year, the firm earned $0.07 earnings per share. The firm's revenue for the quarter was up 12.1% on a year-over-year basis. As a group, analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CERT shares. UBS Group lowered their price target on shares of Certara from $17.50 to $15.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. Morgan Stanley started coverage on shares of Certara in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 price target for the company. Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $11.00 to $14.00 in a research report on Thursday, May 8th. Finally, KeyCorp lowered their price target on shares of Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $15.14.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.